Metabolic-Associated Fatty Liver Disease: The Influence of Oxidative Stress, Inflammation, Mitochondrial Dysfunctions, and the Role of Polyphenols

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(10), P. 1354 - 1354

Published: Oct. 10, 2024

Metabolic-Associated Fatty Liver Disease (MAFLD) is a clinical-pathological scenario that occurs due to the accumulation of triglycerides in hepatocytes which considered significant cause liver conditions and contributes an increased risk death worldwide. Even though possible causes MAFLD can involve interaction genetics, hormones, nutrition, lifestyle (diet sedentary lifestyle) most influential factor developing this condition. Polyphenols comprise many natural chemical compounds be helpful managing metabolic diseases. Therefore, aim review was investigate impact oxidative stress, inflammation, mitochondrial dysfunction, role polyphenols MAFLD. Some reverse part damage related or among them are anthocyanin, baicalin, catechin, curcumin, chlorogenic acid, didymin, epigallocatechin-3-gallate, luteolin, mangiferin, puerarin, punicalagin, resveratrol, silymarin. These have actions reducing plasma enzymes, body mass index, waist circumference, adipose visceral indices, lipids, glycated hemoglobin, insulin resistance, HOMA index. They also reduce nuclear factor-KB (NF-KB), interleukin (IL)-1β, IL-6, tumor necrosis factor-α (TNF-α), blood pressure, fat content, steatosis fibrosis. On other hand, they improve HDL-c, adiponectin levels, fibrogenesis markers. results show promising prevention treatment

Language: Английский

Factores de riesgo de esteatosis hepática metabólica con alta sospecha de fibrosis avanzada en pacientes delgados atendidos en el Hospital Nacional Dos de Mayo 2012-2022

Revista de Gastroenterología del Perú, Journal Year: 2025, Volume and Issue: 45(1), P. 16 - 23

Published: March 31, 2025

Objetivo: Determinar los factores de riesgo sociodemográficos, antropométricos, bioquímico- metabólicos, y presencia comorbilidades asociados a esteatosis hepática metabólica con alta sospecha fibrosis avanzada en pacientes delgados comparados sobrepeso u obesidad, atendidos el Hospital Nacional Dos Mayo 2012- 2022. Materiales métodos: La muestra incluyó 160 pacientes, 80 casos controles historias clínicas Consultorio Endocrinología. investigación fue tipo cuantitativo, observacional analítico controles. Evaluó variables sociodemográficas, clínicas, bioquímicas comorbilidades. Se empleó análisis descriptivo. aplicó pruebas Chi cuadrado , cálculo OR e intervalo confianza se realizó un regresión logística para evaluar confusoras. Resultados: Sociodemográficos: 77,5% sexo femenino 36,3% mayor 60 años p<0,05. Antropométricos: 52,5% tenían perímetro abdominal anormal. Bioquímico: 83,8% HDL bajo p<0,05 10,6; 68,8% hipercolesterolemia <0,05; 72,5% hipertrigliceridemia 1,78; 61,3% HbA1c elevado p=0,48; 86,3% LDL p>0,05 93,8%, Ferritina aumentada 11,8. Clínico: Síndrome metabólico 1,22 (0,9-1,44) dentro las 62,5% presentaron diabetes mellitus p=0,26. Tras logística: Ferritina, disminuido valor Conclusiones: ferritina aumentada, influyen aparición la disfunción asociada 2012-2022.

Assessing Mortality Disparities Among Non-Alcoholic Fatty Liver Disease Metabolic Dysfunction Fatty Liver Disease and Metabolic Dysfunction-Associated Liver Disease: A Comprehensive Meta-Analysis

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 16, 2024

Non-alcoholic fatty liver disease (NAFLD) has emerged as a major global health concern due to its association with increased mortality. While previous studies have indicated link between NAFLD and mortality, variations in risk factors such age, sex, severity warrant comprehensive meta-analysis clarify these associations. This aimed evaluate the overall cardiovascular (CVD) mortality associated NAFLD, considering various subgroups defined by severity, presence of cirrhosis or fibrosis, study quality, follow-up duration. A systematic search eight was conducted assess hazard ratios (HRs) for all-cause CVD NAFLD. Heterogeneity among evaluated using I² statistic, subgroup analyses were performed based on participant significantly an (HR = 1.34, 95% CI: 1.17-1.54, 80.0%). Subgroup revealed that individuals aged ≥50 years 1.50, 1.31-1.73) males 1.43, 1.29-1.59) had higher risk. Patients nonalcoholic steatohepatitis (NASH) showed significant both 1.37, 1.14-1.65) 1.56, 1.25-1.97). The fibrosis further elevated 3.22, 2.40-4.33). However, not analysis 1.13, 0.92-1.38). high across most subgroups, indicating varying effects characteristics. is particularly older individuals, males, those NASH cirrhosis/fibrosis. but evident specific subgroups. These findings underscore importance early detection tailored management mitigate impact Further research needed elucidate mechanisms linking adverse outcomes develop effective interventions.

Language: Английский